The limited effects of pan-PI3K inhibitors and rapamycin analogs in the clinic provide a rationale for trials with drugs targeting both PI3K and mTOR for glioma treatment (Chang et al., 2005; Galanis et al., 2005). This evidence concerns the gene MTOR and central nervous system cancer.